| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | -0.0055 | 0.9 |
| mRNA | OSI-027 | CTRPv2 | pan-cancer | AAC | 0.0025 | 0.9 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.0022 | 0.9 |
| mRNA | selumetinib:vorinostat (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0024 | 0.9 |
| mRNA | MLN2480 | CTRPv2 | pan-cancer | AAC | -0.0035 | 0.9 |